Myelodysplasia
59
6
13
32
Key Insights
Highlights
Success Rate
76% trial completion
Published Results
17 trials with published results (29%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
16.9%
10 terminated out of 59 trials
76.2%
-10.3% vs benchmark
8%
5 trials in Phase 3/4
53%
17 of 32 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 32 completed trials
Clinical Trials (59)
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
Multicenter Observational Study on Myocardial Iron Overload in 3 Multitransfused Populations
Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic Malignancies and Myelodysplasia
ATG Plus PTCy vs ATG for CGVHD Prophylaxis
MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents
MargheRITA (Remote Intelligence for Therapeutic Adherence)
Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes
Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT
TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)
Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients
Haploidentical Stem Cell Transplant With or Without NK Cell Infusion in AML and MDS
Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant